Document Detail

Advanced prostate cancer-a case for adjuvant differentiation therapy.
MedLine Citation:
PMID:  22890299     Owner:  NLM     Status:  Publisher    
The development of novel therapies such as abiraterone acetate and sipuleucel-T has improved the outlook for patients with advanced-stage and castration-resistant prostate cancer. However, the beneficial effects of these drugs are only measured in months. Moreover, the National Institute for Health and Clinical Excellence in the UK had ruled that the use of abiraterone acetate was not cost-effective before cost revision by the manufacturers. The FDA statement asserting that the use of 5α-reductase inhibitors for prostate cancer chemoprevention could increase the risk of developing high-grade prostate cancer also indirectly questions the value of direct androgen response manipulation for long-term benefit. These reports illustrate the need for a fresh and comprehensive analysis of advanced prostate cancer pathology to promote the next generation of effective adjuvant therapies. One such avenue is that of differentiation therapy, which seeks to promote the differentiation of cancer stem cells into a phenotype more sensitive to anticancer therapy than their parents. Using differentiation therapy with current antiandrogen therapies should augment our armoury of treatment for the management of advanced prostate cancer.
Jayant K Rane; Davide Pellacani; Norman J Maitland
Related Documents :
22575759 - From modules to medicine: how modular domains and their associated networks can enable ...
23459799 - The diagnostic and prognostic role of microrna in colorectal cancer - a comprehensive r...
12903009 - Normal tissue effects: reporting and analysis.
12022369 - Dna ploidy and cytonuclear area of peritumoral and paratumoral samples of mastectomy sp...
22319019 - Second primary lung cancer after head and neck squamous cell cancer: population-based s...
24172539 - Modeling the adenoma and serrated pathway to colorectal cancer (ascca).
20682629 - Azygos flap as a novel method for superior vena cava reconstruction.
15626639 - Ionizing radiation and chronic lymphocytic leukemia.
24360659 - Pharmacogenomics in bladder cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-14
Journal Detail:
Title:  Nature reviews. Urology     Volume:  -     ISSN:  1759-4820     ISO Abbreviation:  Nat Rev Urol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500082     Medline TA:  Nat Rev Urol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Yorkshire Cancer Research Unit, Department of Biology (Area 13), University of York, York YO10 5DD, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of Laryngeal Findings on Acoustic Parameters of Patients with Laryngopharyngeal Reflux.
Next Document:  Normal and neoplastic urothelial stem cells: getting to the root of the problem.